Allurion Stock Triples on Plan to Test Gastric Balloon With Obesity Drugs
1. Allurion to study gastric balloon with GLP-1 drugs for improved muscle mass. 2. Previous GLP-1 users lost significant lean mass; Allurion aims to combat this. 3. Shares tripled on news but remain down over 85% in the past year. 4. Potential successful combo could set new standard in obesity treatment.